News

The founding president and chief executive officer of Parent Project Muscular Dystrophy discussed recent and upcoming milestones in the field.

Among 12 patients evaluable for efficacy, 10 patients experienced stabilization or improvement from baseline in BCVA in their treated eyes.

Opus Genetics plans to add a pediatric cohort to the phase 1/2 trial once safety is established in adults.

Juan Francisco Cabello, MD, the head of the Pediatric Neurology Fellowship Program at the University of Valparaíso in Chile, discussed the current state of newborn screening and what needs to change.

The trial has dosed its third patient, and, safety validation pending, plans to dose a second cohort beginning at the end of 2023.

The PDUFA data has been set for March 18, 2024.

The companies plan to evaluate the combination therapy in patients with HL in the phase 2 LuminICE-203 clinical trial.

The chief scientific officer of CureDuchenne discussed progress in the field so far and upcoming milestones.

The study will utilize a pediatric safety run-in that will include 2 patients.

The postdoctoral fellow and member of the La Spada Lab at University of California, Irvine, discussed findings he presented at ANA’s 2023 conference that may have implications for future RNA therapy development.

The FDA has accepted the company’s plan to address its current IND clinical hold on HEMO-CAR-T.

Review top news and interview highlights from the week ending September 15, 2023.

The chief scientific officer at Omega Therapeutics discussed the issues with other modes of therapies that OEC therapy may address.

Kyverna stated that the patient, who received KYV-101 in July at the University of Colorado Anschutz Medical Campus, did not experience any ICANS.

Patients were newly diagnosed and had acute myeloid leukemia positive for FLT3-iTD mutations.

The head of the Pediatric Neurology Fellowship Program at the University of Valparaiso in Chile discussed how a lack of cost-effectiveness may hold back the potential of newborn screening in gene therapy.

A final analysis of data from CARTITUDE-1 was also presented at SOHO 2023, which revealed a PFS of 24.9 months in treated patients.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Sattar Khoshkhoo, MD, the founding director of the Epilepsy Genetics Clinic at Brigham and Women's Hospital, discussed his nonclinical research on disease pathogenesis in MTLE.

Adstiladrin was approved in December 2022 and is now available for select patients under an Early Experience Program.

Novartis stated that the decision was made in light of a recommendation from an independent data monitoring committee.

The chief research officer, Muscular Dystrophy Association, shared a message for Duchenne Action Month.

SynKIR-110 is based off of the KIR-CAR platform developed at the University of Pennsylvania.

The head of the Pediatric Neurology Fellowship Program at the University of Valparaíso in Chile discussed positive impact of newborn screening so far and work that still needs to be done.

Beam Therapeutics also expects to announce initial data from its BEACON trial in sickle cell in 2024.

The company also announced its plans for a modified study protocol that may allow a roadway to approval.

Study author Mya C. Schiess, MD, commented on trends seen in the blinded findings so far.

Zilebesiran is being evaluated as a monotherapy in the KARDIA-1 study and as a combination therapy in KARDIA-2, which will report topline data in early 2024.